Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 2Thoracic 1Lymphoid 1CNS 1

Conditions

Central Nervous System Neoplasms 6Neuroblastoma 4Testicular Neoplasms 3Testicular Germ Cell Tumor 3Brain Neoplasms 3Seminoma 2Pheochromocytoma 2Ovarian Neoplasms 2Medulloblastoma 2Glioma 2Endodermal Sinus Tumor 2Thrombocytopenia 1Teratoma 1Microphthalmia, Isolated, with Coloboma 5 1Lymphoma 1Intraocular Lymphoma 1Gliosarcoma 1Glioblastoma 1Dysgerminoma 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Embryonal 1

Interventions

sodium thiosulfate 3Filgrastim 3Carboplatin 3etoposide phosphate 2Cyclophosphamide 2pegfilgrastim 1Vincristine 1Trastuzumab 1Temozolomide 1Rituximab 1Procarbazine 1Methotrexate 1Mannitol 1Lomustine 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Genetic Therapy 1Etoposide 1Cytarabine 1Cefixime 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × pegfilgrastim × CNS × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡